In many ways, Viatris is a product of the recent challenges faced by copycat drug developers.
In the world’s largest pharmaceutical market, the U.S., generics companies have found maintaining profits more difficult because of pressure on prices. At the same time, biosimilar sales remain relatively low due to the complicated patent webs that block many manufacturers from making inroads.
For some of the biggest, most diversified drug companies, these obstacles have raised questions about whether money would be better spent elsewhere. Biogen, for instance, announced in January plans to sell its stake in a joint venture focused on biosimilars. The Swiss pharmaceutical giant Novartis has also said it might offload its struggling generics unit Sandoz.
Viatris, meanwhile, was created through a merger between Pfizer’s generics business, called Upjohn, and Mylan, which had hit a series setbacks manufacturing- and pricing-related setbacks over the preceding few years. READ MORE
by Jacob Bell
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.